Prostate Cancer - Results from #1920

Clarity and PSI Kick Off SAR-bisPSMA Phase III October 27, 2023

Novartis Confirms Unconstrained Supply for Pluvicto® and Continues to Significantly Expand the Number of Treatment Centers October 27, 2023

Robot-Assisted Surgery and Racial and Ethnic Disparities in Post-Prostatectomy Outcomes Among Prostate Cancer Patients. October 27, 2023

Disease control outcomes of stereotactic body radiation therapy or moderate hypo-fractionation for prostate cancer: Real-world experience at two Canadian centers. October 27, 2023

Towards Improving the Efficacy of PSMA-Targeting Radionuclide Therapy for Late-Stage Prostate Cancer-Combination Strategies. October 27, 2023

Pelvic irradiation for node-positive prostate cancer after prostatectomy: Long-term results of the prospective PLATIN-4 and PLATIN-5 trials. October 27, 2023

Longitudinal assessment of plasma androgen receptor copy number predicts overall survival in subsequent treatment lines in castration-resistant prostate cancer: analysis from a prospective trial. October 27, 2023

The long tail of oncogenic drivers in prostate cancer. October 27, 2023

Differential impact of tumor suppressor gene (TP53, PTEN, RB1) alterations and treatment outcomes in metastatic, hormone-sensitive prostate cancer. October 27, 2023

Reliable Prostate Cancer Risk Mapping from MRI Using Targeted and Systematic Core Needle Biopsy Histopathology. October 26, 2023

Androgen deprivation therapy and cardiovascular morbidity in prostate cancer: a narrative review. October 26, 2023

Monitoring Intrafraction Motion of the Prostate During Radiation Therapy: Suggested Practice Points from a Focused Review. October 26, 2023

Impact of peritoneal reconfiguration on lymphocele formation after robot-assisted radical prostatectomy with pelvic lymph node dissection: a systematic review and meta-analysis of randomized controlled trials. October 26, 2023

Overall Survival and Associations of Insurance Status Among Hispanic Men With High-Risk Prostate Cancer. October 26, 2023

Characteristics of incidental prostate cancer in the United States. October 25, 2023

Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study. October 25, 2023

Location and Types of Treatment for Prostate Cancer After the Veterans Choice Program Implementation. October 25, 2023

Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology. October 25, 2023

Long-term Prostate Cancer-specific Mortality After Prostatectomy, Brachytherapy, External Beam Radiation Therapy, Hormonal Therapy, or Monitoring for Localized Prostate Cancer. October 25, 2023

Comparison of Multiparametric Magnetic Resonance Imaging-Targeted Biopsy With Systematic Transrectal Ultrasonography Biopsy for Biopsy-Naive Men at Risk for Prostate Cancer: A Phase 3 Randomized Clinical Trial. October 25, 2023

Page 97 of 1437